Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
about
Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant ApproachesAgomelatine beyond borders: current evidences of its efficacy in disorders other than major depressionRoyal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Novel routes to bipolar disorder drug discovery.Agomelatine in depression.Recent advances in sleep-wake cycle and biological rhythms in bipolar disorder.Agomelatine: an agent against anhedonia and abulia?Circadian clock and stress interactions in the molecular biology of psychiatric disorders.Post-stroke depression and the aging brain.Drugs under early investigation for the treatment of bipolar disorder.Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder.The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.Agomelatine for the treatment of generalized anxiety disorder.Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.Mitochondrial Agents for Bipolar Disorder.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
P2860
Q26738789-7253F7DE-40AE-4B17-B440-175BB65FD158Q28651498-904BE8BE-2577-4460-B14A-AAB1A95DE7BDQ35862776-805A1DDA-85A0-4E2A-9DC7-469A01E60480Q38109244-65424B69-922B-4927-A13C-3C5ECE8067C0Q38137187-20E0FDBD-4992-46F0-A4D7-780DFCB72A10Q38138487-3C3EECE0-7E68-404A-A68E-26C275AC250DQ38169108-B68E6CD4-0A68-4F92-BE75-8D4D9CDD1EC5Q38241135-D2227C2B-5550-474D-BCC3-4136889539B4Q38269517-E8802379-F481-457A-A19E-701A9B72AEF7Q38364032-27557192-E13D-42D6-A585-9FEBE0175143Q38366298-C1BCA3F7-C936-4794-BB7E-3110CA3CF18FQ38366416-4DC07BA5-7E1E-4249-B8F3-1E1F4B71ADEDQ38668480-B92876FE-2DF9-4877-B7B5-77DF075D8287Q47371574-F5ED793F-7B8D-4E01-93DD-D9452D8C5CEDQ52621890-5F330F24-8F42-4AD1-B12C-1DFD8DDDBEF0Q52656684-3745E1BE-9832-49B3-9B06-8F6CCA6E375B
P2860
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Adjunctive agomelatine therapy ...... a preliminary open label study
@ast
Adjunctive agomelatine therapy ...... a preliminary open label study
@en
Adjunctive agomelatine therapy ...... a preliminary open label study
@nl
type
label
Adjunctive agomelatine therapy ...... a preliminary open label study
@ast
Adjunctive agomelatine therapy ...... a preliminary open label study
@en
Adjunctive agomelatine therapy ...... a preliminary open label study
@nl
prefLabel
Adjunctive agomelatine therapy ...... a preliminary open label study
@ast
Adjunctive agomelatine therapy ...... a preliminary open label study
@en
Adjunctive agomelatine therapy ...... a preliminary open label study
@nl
P2093
P2860
P50
P3181
P356
P1476
Adjunctive agomelatine therapy ...... a preliminary open label study
@en
P2093
Carlo Ignazio Cattaneo
Emanuela D'Angelo
Massimo Tabaton
Matteo Martino
Pantaleo Fornaro
Salvatore Colicchio
P2860
P304
P3181
P356
10.2147/NDT.S41557
P407
P577
2013-01-01T00:00:00Z